The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
IL-1F5, -F6, -F8, and -F9: A Novel IL-1 Family Signaling System That Is Active in Psoriasis and Promotes Keratinocyte Antimicrobial Peptide Expression
Open accessAbstract
IL-1F6, IL-1F8, and IL-1F9 and the IL-1R6(RP2) receptor antagonist IL-1F5 constitute a novel IL-1 signaling system that is poorly characterized in skin. To further characterize these cytokines in healthy and inflamed skin, we studied their expression in healthy control, uninvolved psoriasis, and psoriasis plaque skin using quantitative RT-PCR and immunohistochemistry. Expression of IL-1F5, -1F6, -1F8, and -1F9 were increased 2 to 3 orders of magnitude in psoriasis plaque versus uninvolved psoriasis skin, which was supported immunohistologically. Moreover, treatment of psoriasis with etanercept led to significantly decreased IL-1F5, -1F6, -1F8, and -1F9 mRNAs, concomitant with clinical improvement. Similarly increased expression of IL-1F5, -1F6, -1F8, and -1F9 was seen in the involved skin of two mouse models of psoriasis. Suggestive of their importance in inflamed epithelia, IL-1α and TNF-α induced IL-1F5, -1F6, -1F8, and -1F9 transcript expression by normal human keratinocytes. Microarray analysis revealed that these cytokines induce the expression of antimicrobial peptides and matrix metalloproteinases by reconstituted human epidermis. In particular, IL-1F8 increased mRNA expression of human β-defensin (HBD)-2, HBD-3, and CAMP and protein secretion of HBD-2 and HBD-3. Collectively, our data suggest important roles for these novel cytokines in inflammatory skin diseases and identify these peptides as potential targets for antipsoriatic therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Summaries of Affymetrix GeneChip probe level data
Irizarry, R. A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng015 · Cited by 4,887
Dermatology in General Medicine.
(1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-106-6-923_2 · Cited by 3,794
Schmitz, J., Owyang, A., Oldham, E., Song, Y., Murphy, E., McClanahan, T. K., Zurawski, G., Moshrefi, M., Qin, J., Li, X., et al. (2005) · Immunity · doi:10.1016/j.immuni.2005.09.015 · Cited by 3,710
Veldhoen, M., Hocking, R. J., Atkins, C. J., Locksley, R. M., & Stockinger, B. (2006) · Immunity · doi:10.1016/j.immuni.2006.01.001 · Cited by 3,605 · cited 1×
“IL-1 was the first cytokine discovered in skin (49), and with the discovery that IL-1 is crucial for T cell differentiation (50, 51), IL-1 immunobiology is undergoing a renaissance.”
BackgroundImmunological and inflammatory functions of the interleukin-1 family
Dinarello, C. A. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132612 · Cited by 3,466
Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis
van der Fits, L., Mourits, S., Voerman, J. S. A., Kant, M., Boon, L., Laman, J. D., Cornelissen, F., Mus, A.-M., Florencia, E., Prens, E. P., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802999 · Cited by 2,176
Self-citationAgostini, L., Martinon, F., Burns, K., McDermott, M. F., Hawkins, P. N., & Tschopp, J. (2004) · Immunity · doi:10.1016/s1074-7613(04)00046-9 · Cited by 1,768 · cited 1×
“Further, given that we have shown that these new IL-1 family members are able to drive AMP expression in skin and generate a psoriasis-like gene expression profile, it is possible that the use of an IL-1R6 antagonist, analogous to IL-1ra/anakinra in the cryopyrin-associated periodic syndromes (52, 53) and rheumatoid a…”
BackgroundEtanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
Mease, P. J., Goffe, B. S., Metz, J., VanderStoep, A., Finck, B., & Burge, D. J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02530-7 · Cited by 1,446
The IL-1 family: regulators of immunity
Sims, J. E., & Smith, D. E. (2010) · Nature Reviews Immunology · doi:10.1038/nri2691 · Cited by 1,418
Fitzpatrick’s Dermatology in General Medicine
Dunnick, C. A. (2008) · JAMA · doi:10.1001/jama.299.10.1195-b · Cited by 1,162
Cited by
Griffiths, C. E. M., Armstrong, A. W., Gudjonsson, J. E., & Barker, J. N. W. N. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32549-6 · Cited by 2,383
Self-citationNF-κB: At the Borders of Autoimmunity and Inflammation
Barnabei, L., Laplantine, E., Mbongo, W., Rieux-Laucat, F., & Weil, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.716469 · Cited by 630
The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses
Lowes, M. A., Russell, C. B., Martin, D. A., Towne, J. E., & Krueger, J. G. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.11.005 · Cited by 537
Onoufriadis, A., Simpson, M. A., Pink, A. E., Di Meglio, P., Smith, C. H., Pullabhatla, V., Knight, J., Spain, S. L., Nestle, F. O., Burden, A. D., et al. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.07.022 · Cited by 529
Proteolytic Processing of Interleukin-1 Family Cytokines: Variations on a Common Theme
Afonina, I. S., Müller, C., Martin, S. J., & Beyaert, R. (2015) · Immunity · doi:10.1016/j.immuni.2015.06.003 · Cited by 490
Perera, G. K., Di Meglio, P., & Nestle, F. O. (2012) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132448 · Cited by 462
Pathogenesis of psoriasis and development of treatment
Ogawa, E., Sato, Y., Minagawa, A., & Okuyama, R. (2018) · The Journal of Dermatology · doi:10.1111/1346-8138.14139 · Cited by 456
Signaling pathways and targeted therapies for psoriasis
Guo, J., Zhang, H., Lin, W., Lu, L., Su, J., & Chen, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01655-6 · Cited by 427
Carrier, Y., Ma, H.-L., Ramon, H. E., Napierata, L., Small, C., O'Toole, M., Young, D. A., Fouser, L. A., Nickerson-Nutter, C., Collins, M., et al. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.234 · Cited by 425
PSORS2 Is Due to Mutations in CARD14
Jordan, C. T., Cao, L., Roberson, E. D. O., Pierson, K. C., Yang, C.-F., Joyce, C. E., Ryan, C., Duan, S., Helms, C. A., Liu, Y., et al. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2012.03.012 · Cited by 416
Psoriasiform dermatitis is driven by IL-36–mediated DC-keratinocyte crosstalk
Tortola, L., Rosenwald, E., Abel, B., Blumberg, H., Schäfer, M., Coyle, A. J., Renauld, J.-C., Werner, S., Kisielow, J., & Kopf, M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63451 · Cited by 405
IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis
Johnston, A., Xing, X., Wolterink, L., Barnes, D. H., Yin, Z., Reingold, L., Kahlenberg, J. M., Harms, P. W., & Gudjonsson, J. E. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.08.056 · Cited by 397
Self-citationvan de Veerdonk, F. L., Stoeckman, A. K., Wu, G., Boeckermann, A. N., Azam, T., Netea, M. G., Joosten, L. A. B., van der Meer, J. W. M., Hao, R., Kalabokis, V., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121534109 · Cited by 380
Baliwag, J., Barnes, D. H., & Johnston, A. (2015) · Cytokine · doi:10.1016/j.cyto.2014.12.014 · Cited by 373
Self-citationSix reference-quality genomes reveal evolution of bat adaptations
Jebb, D., Huang, Z., Pippel, M., Hughes, G. M., Lavrichenko, K., Devanna, P., Winkler, S., Jermiin, L. S., Skirmuntt, E. C., Katzourakis, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2486-3 · Cited by 361
The Immunology of Psoriasis-Current Concepts in Pathogenesis
Sieminska, I., Pieniawska, M., & Grzywa, T. M. (2024) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-024-08991-7 · Cited by 346
Hirota, T., Takahashi, A., Kubo, M., Tsunoda, T., Tomita, K., Sakashita, M., Yamada, T., Fujieda, S., Tanaka, S., Doi, S., et al. (2012) · Nature Genetics · doi:10.1038/ng.2438 · Cited by 346
Neutrophil-Derived Proteases Escalate Inflammation through Activation of IL-36 Family Cytokines
Henry, C. M., Sullivan, G. P., Clancy, D. M., Afonina, I. S., Kulms, D., & Martin, S. J. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.072 · Cited by 330
Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation
Johnston, A., Fritz, Y., Dawes, S. M., Diaconu, D., Al-Attar, P. M., Guzman, A. M., Chen, C. S., Fu, W., Gudjonsson, J. E., McCormick, T. S., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201505 · Cited by 308
Self-citationIL-36R ligands are potent regulators of dendritic and T cells
Vigne, S., Palmer, G., Lamacchia, C., Martin, P., Talabot-Ayer, D., Rodriguez, E., Ronchi, F., Sallusto, F., Dinh, H., Sims, J. E., et al. (2011) · Blood · doi:10.1182/blood-2011-05-356873 · Cited by 308
IL-36 Promotes Myeloid Cell Infiltration, Activation, and Inflammatory Activity in Skin
Foster, A. M., Baliwag, J., Chen, C. S., Guzman, A. M., Stoll, S. W., Gudjonsson, J. E., Ward, N. L., & Johnston, A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301481 · Cited by 302
Self-citationInterleukin-17A and Keratinocytes in Psoriasis
Furue, M., Furue, K., Tsuji, G., & Nakahara, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041275 · Cited by 300
TLRs to cytokines: Mechanistic insights from the imiquimod mouse model of psoriasis
Flutter, B., & Nestle, F. O. (2013) · European Journal of Immunology · doi:10.1002/eji.201343801 · Cited by 291
Ma, F., Plazyo, O., Billi, A. C., Tsoi, L. C., Xing, X., Wasikowski, R., Gharaee-Kermani, M., Hile, G., Jiang, Y., Harms, P. W., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39020-4 · Cited by 284
Self-citationBoutet, M.-A., Bart, G., Penhoat, M., Amiaud, J., Brulin, B., Charrier, C., Morel, F., Lecron, J.-C., Rolli-Derkinderen, M., Bourreille, A., et al. (2016) · Clinical and Experimental Immunology · doi:10.1111/cei.12761 · Cited by 275
Current knowledge on psoriasis and autoimmune diseases
McCormick, T., Ayala-Fontanez, N., & Soler, D. (2016) · Psoriasis: Targets and Therapy · doi:10.2147/ptt.s64950 · Cited by 266
Therapeutic potential of MCC950, a specific inhibitor of NLRP3 inflammasome
Li, H., Guan, Y., Liang, B., Ding, P., Hou, X., Wei, W., & Ma, Y. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175091 · Cited by 258
Brunner, P. M., Israel, A., Zhang, N., Leonard, A., Wen, H.-C., Huynh, T., Tran, G., Lyon, S., Rodriguez, G., Immaneni, S., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.02.040 · Cited by 256
IL-36γ (IL-1F9) Is a Biomarker for Psoriasis Skin Lesions
D'Erme, A. M., Wilsmann-Theis, D., Wagenpfeil, J., Hölzel, M., Ferring-Schmitt, S., Sternberg, S., Wittmann, M., Peters, B., Bosio, A., Bieber, T., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.532 · Cited by 252
Tsuji, G., Yamamura, K., Kawamura, K., Kido-Nakahara, M., Ito, T., & Nakahara, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914633 · Cited by 21
Metadata
- Authors
- Johnston, A., Xing, X., Guzman, A. M., Riblett, M., Loyd, C. M., Ward, N. L., Wohn, C., Prens, E. P., Wang, F., Maier, L. E., Kang, S., Voorhees, J. J., Elder, J. T., & Gudjonsson, J. E.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-02
- Volume
- 186
- Issue
- 4
- Pages
- 2613-2622
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2170640435
- Cited by
- 319
- References
- 52
- FWCI
- 10.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.